ArticleScientific reports2012
Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease.
Article in Scientific reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Network Analysis Identifies Disease-Specific Pathways for Parkinson's Disease.Molecular neurobiology · 2018Pooled it
- Transaldolase 1 impacts Parkinson's disease pathogenesis via metabolic reprogramming and autophagy-lysosomal pathway.Acta neuropathologica communications · 2025Article
- Review
- Shared and Unique Disease Pathways in Amyotrophic Lateral Sclerosis and Parkinson's Disease Unveiled in Peripheral Blood Mononuclear Cells.ACS chemical neuroscience · 2023Article
- Current Insights on Neurodegeneration by the Italian Proteomics Community.Biomedicines · 2022Review
- Beta2-Adrenoceptor Agonists in Parkinson's Disease and Other Synucleinopathies.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.Journal of neurochemistry · 2019Review
- Inflammation, Infectious Triggers, and Parkinson's Disease.Frontiers in neurology · 2019Review
- Probiotics May Have Beneficial Effects in Parkinson's Disease:Frontiers in immunology · 2019Article
- Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells.Journal of translational medicine · 2018Article
- The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases.Molecular neurodegeneration · 2017Review
- α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology.Journal of neuroinflammation · 2016Article
- Differential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's disease.International journal of clinical and experimental pathology · 2015Article
- Predicting cognitive decline in Parkinson's disease: can we ask the genes?Frontiers in neurology · 2014Review
- The role of innate and adaptive immunity in Parkinson's disease.Journal of Parkinson's disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of Parkinson's disease (PD) is currently based on the clinical evaluation of extrapyramidal signs with a considerable error rate. The identification of specific markers might allow PD diagnosis before the onset of classical motor symptoms. By two-dimensional electrophoresis we identified proteome alterations in T-lymphocytes of 17 control subjects and 15 PD patients. The observed changes were used to build predictive models that were verified by the leave-one-out cross-validation. We further built two functions able to stage the subjects. We chose to verify by Western blotting the identity of spots corresponding to β-fibrinogen and transaldolase, two recurrent proteins in six out of 20 spots. β-Fibrinogen levels are lowered in PD patients, whereas a heavy transaldolase set of isoforms was more abundant. Eventually, we identified a list of seven proteins showing different levels in early-onset with respect to late-onset PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.